Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00183898 | Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 75 | University of Southern CaliforniaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT01134575 | CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT01797523 | A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02654119 | Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery | completed | Phase 2 | 20 | University of NebraskaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03606837 | 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging(PROSTATEP) | completed | Phase 2 | 14 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04263584 | Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL(COPA-R-CHOP) | completed | Phase 2 | 62 | University Hospital MuensterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06076135 | Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors(ILDR-01) | completed | Phase 2 | 24 | Chuangzhen ChenOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT00505063 | Prospective Trial of Vaccine Responses in Childhood Cancer Survivors | completed | Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03264131 | BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma | completed | Phase 2 | 16 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05258279 | Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations | completed | Phase 2 | 30 | Juntendo UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03556384 | Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 23 | Adam Burgoyne, MD, PhDOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03581487 | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04563871 | Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)(BLOSSOM) | completed | Phase 2 | 73 | Sehhoon ParkOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05282901 | Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)(PLUME) | completed | Phase 2 | 51 | Institut CurieOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT00429312 | A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma | completed | Phase 1 / Phase 2 | 10 | Jennerex BiotherapeuticsINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT01339052 | Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma | completed | Phase 2 | 65 | L. Nicolas Gonzalez Castro, MD, PhDOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT04975555 | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | completed | Phase 2 | 20 | University of Alabama at BirminghamOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06604858 | Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer(TELESCOPE) | completed | Phase 2 | 31 | MedSIROTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02252887 | Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | completed | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02876302 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03672539 | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05117957 | Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study | completed | Phase 2 | 50 | Bo Hyun KimOTHER_GOV | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05278975 | Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | completed | Phase 1 / Phase 2 | 50 | RS Oncology LLCINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06614140 | Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 8 | Seqker Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02821559 | Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer(EROS) | completed | Phase 2 | 37 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02905578 | A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) | completed | Phase 2 | 40 | University of IowaOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03374332 | Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 11 | Brown UniversityOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03410030 | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)(AA NABPLAGEM) | completed | Phase 1 / Phase 2 | 17 | HonorHealth Research InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03836209 | Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | completed | Phase 2 | 181 | PrECOG, LLC.OTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05005715 | Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery | completed | Phase 2 | 64 | Seoul National University HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT00076310 | OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03796767 | Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer(SOAR) | completed | Phase 2 | 20 | University of UtahOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04776447 | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)(APOLO) | completed | Phase 2 | 38 | Fundación GECPOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07720011 | Interim PET/CT-adapted Use of PD-1 Inhibitor Combined With De-escalated Chemotherapy-AVD in Classic Hodgkin Lymphoma | completed | Phase 2 | 130 | Peking University People's HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT01708941 | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02337829 | Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL | completed | Phase 2 | 48 | Acerta Pharma BVINDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02389244 | A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas(REGOBONE) | completed | Phase 2 | 163 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03006848 | A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma | completed | Phase 2 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04537286 | First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients | completed | Phase 2 | 90 | Fudan UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04669197 | Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer | completed | Phase 2 | 19 | HonorHealth Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04702009 | Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 33 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04826341 | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | completed | Phase 1 / Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04930315 | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma(CAPT) | completed | Phase 2 | 78 | Zhejiang UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05512377 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | completed | Phase 2 | 99 | Boehringer IngelheimINDUSTRY | 16 | Jul 21, 2026 | clinicaltrials |
| NCT01750567 | A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL | completed | Phase 2 | 37 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03455504 | Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia(V-FIRST) | completed | Phase 2 | 124 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04164979 | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma | completed | Phase 2 | 34 | University of California, IrvineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04743934 | Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer(RAD 2003) | completed | Phase 2 | 44 | Andrew McDonaldOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04758780 | Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer(OPALESCENCE) | completed | Phase 2 | 12 | Institut Cancerologie de l'OuestOTHER | 1 | Jul 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 30, 2026source: clinicaltrials